Tymlos was recommended but the osteosarcoma risk is frightening

The osteosarcoma warning is real, but the fracture benefit is large and well-proven; the question is whether your personal risk profile justifies it.

The ACTIVE trial, the main evidence for Tymlos, is a randomized, placebo-controlled study with hard clinical endpoints: it cut new vertebral fractures from about 4 in 100 women on placebo to under 1 in 100 on the drug over 18 months [1][3]. Nonvertebral fractures fell from about 5 in 100 to under 3 in 100 [1]. Those are real outcomes, not lab surrogates. The extension study, ACTIVExtend, kept the benefit: after 43 months, vertebral fractures were under 1 in 100 in the Tymlos-first group versus about 6 in 100 in placebo-first [2][3]. Hip fractures were zero versus five [2].

The osteosarcoma fear comes from animal studies, not human data. The trials reported no osteosarcoma cases, but they were too small and too short to detect a rare cancer [1][2][3]. The drug is limited to two years of lifetime use precisely because of that theoretical risk [2]. No long-term human safety registry exists in these records.

The evidence base is also narrow: it covers postmenopausal women only, not men or younger patients [1][3]. And the pivotal trial was manufacturer-funded, which is standard but worth naming.

My call: if you are a postmenopausal woman with high fracture risk, the fracture benefit likely outweighs the theoretical osteosarcoma risk, but the absence of long-term human safety data means you are accepting an unquantified risk. Confidence: moderate.